BioNTech and Bristol Myers Squibb Partner on $10 Billion Oncology Immunotherapy Agreement

Retrieved on: 2025-06-07 21:11:34

Tags for this article:

Click the tags to see associated articles and topics

BioNTech and Bristol Myers Squibb Partner on $10 Billion Oncology Immunotherapy Agreement. View article details on hiswai:

Excerpt

BioNTech and Bristol Myers Squibb (BMS) have entered into a partnership to advance an oncology-focused agreement valued at over $10 billion.

Article found on: www.geneonline.com